Phase I clinical trials, using αGalCer-loaded DCs to target iNKT cells, have shown promise in treating some patients with cancer. As humans have a low frequency of iNKT cells, therapies that combine ...
Immunotherapy. 2011;3(10):1167-1184. In this review we will denote NKT cells as NKT cells when describing studies that did not differentiate between type I and type II NKT cells and type I invariant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results